Skip to main content

Protara Therapeutics, Inc.

corporate_fare Company Profile

Protara Therapeutics, Inc.

TARA·NASDAQ·Life Sciences·CIK 0001359931

Protara Therapeutics, Inc. is a New York City-based clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. The company's portfolio includes two development programs utilizing TARA-002, an investigational cell therapy. TARA-002 is based on OK-432, a broad immunopotentiator originally approved by the Japanese Ministry of Health and Welfare as an immunopotentiating cancer therapeutic agent. This cell therapy is currently approved in Japan and Taiwan for lymphatic malformations (LMs) and multiple oncologic indications. Protara Therapeutics has worldwide rights to TARA-002, excluding Japan and Taiwan, and is exploring its use in oncology and rare disease indications. TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432 (marketed as Picibanil® in Japan by Chugai Pharmaceutical Co., Ltd.). The company is currently developing TARA-002 for non-muscle invasive bladder cancer (NMIBC) and LMs. Protara Therapeutics is also developing IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, which includes both nutrition and fluids. Neither TARA-002 nor IV Choline Chloride have been approved by the FDA or other comparable regulatory authorities for any indications. The company has not generated any revenues from product sales to date.

Protara Therapeutics, Inc. (NASDAQ:TARA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for TARA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for TARA spans 8-K, 10-Q, 4, 144.

Recent high-impact activity:

  • Protara Q3 Loss Widens to $21.7M; Buys Novex Manufacturing Assets for $8.75M
  • Q3 Cash Drops to $143M as Net Loss Widens to $21.7M; STARBORN-1 Enrollment Slips to 1Q 2027
  • Protara Q2 Loss Widens to $21.7M; Cash Runway Extends into 2028 but Burn Accelerates
  • Protara Q2 2026: $161.9M Cash Runway and Pipeline Milestones on Track
  • Protara Reports Q2 Cash of $162M, Advances Bladder Cancer and Rare Disease Programs

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$57.44M
Diluted EPS
-$1.34
Op. Cash Flow
-$56.37M
Free Cash Flow
-$56.46M
Operating Income
-$64.55M
Cash & Equivalents
$49.66M
Debt / Equity
0.00×
Shares Outstanding
53.59M sh
Source: 10-K · filed 2026-03-10 · accession 0001213900-26-025433

Short Interest & Short Volume

2.87 days to cover

FINRA reported short interest of 3,236,659 shares in TARA as of the October 30, 2026 settlement, a 46.9% decrease from the prior period — about 2.9 days to cover at its recent average daily volume. On November 20, 2026, 54.8% of TARA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,236,659 shares as of October 30, 2026
Change vs prior period▼ 46.9%
Days to cover2.87 at avg daily volume of 1,127,185
Daily short volume (FINRA facilities)54.8% of 538,673 shares on November 20, 2026
5-day average short volume49.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for TARA, detected from its recent SEC filings · based on capital-structure filings through 2026-06-15.

1 recent capital raiseATM program

At-The-Market Offering Launched · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with T →
$2.28
52-week range · as of 2026-11-06 $2.11 – $7.82
Market cap
$140.38M
Volume
1.1M (1.2× avg)
3-mo avg 922.1K
Live data · 2026-11-22 12:03 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TARA - Latest Insights

TARA
Nov 06, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.11
Real-time Price: $2.28 info
Change: +$0.170 (+8%) info
Market Cap: $140.38M info
TARA
Nov 06, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.11
Real-time Price: $2.28 info
Change: +$0.170 (+8%) info
Market Cap: $140.38M info
TARA
Aug 11, 2026, 8:10 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.98
Real-time Price: $2.28 info
Change: -$1.70 (-43%) info
Market Cap: $140.38M info
TARA
Aug 11, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.98
Real-time Price: $2.28 info
Change: -$1.70 (-43%) info
Market Cap: $140.38M info
TARA
Aug 11, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.98
Real-time Price: $2.28 info
Change: -$1.70 (-43%) info
Market Cap: $140.38M info
TARA
Jul 01, 2026, 4:10 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $4.04
Real-time Price: $2.28 info
Change: -$1.76 (-44%) info
Market Cap: $140.38M info
TARA
Jun 29, 2026, 5:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.16
Real-time Price: $2.28 info
Change: -$1.88 (-45%) info
Market Cap: $140.38M info
TARA
Jun 29, 2026, 4:52 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $4.16
Real-time Price: $2.28 info
Change: -$1.88 (-45%) info
Market Cap: $140.38M info
TARA
Jun 15, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.94
Real-time Price: $2.28 info
Change: -$1.66 (-42%) info
Market Cap: $140.38M info
TARA
May 28, 2026, 4:46 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.74
Real-time Price: $2.28 info
Change: -$2.46 (-52%) info
Market Cap: $140.38M info
TARA
May 28, 2026, 4:30 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $4.75
Real-time Price: $2.28 info
Change: -$2.47 (-52%) info
Market Cap: $140.38M info
TARA
May 15, 2026, 7:01 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $5.39
Real-time Price: $2.28 info
Change: -$3.11 (-58%) info
Market Cap: $140.38M info
TARA
May 13, 2026, 7:17 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $5.20
Real-time Price: $2.28 info
Change: -$2.92 (-56%) info
Market Cap: $140.38M info
TARA
May 13, 2026, 8:10 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.15
Real-time Price: $2.28 info
Change: -$2.87 (-56%) info
Market Cap: $140.38M info
TARA
May 13, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.15
Real-time Price: $2.28 info
Change: -$2.87 (-56%) info
Market Cap: $140.38M info
TARA
May 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.15
Real-time Price: $2.28 info
Change: -$2.87 (-56%) info
Market Cap: $140.38M info
TARA
Apr 23, 2026, 8:42 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $5.26
Real-time Price: $2.28 info
Change: -$2.98 (-57%) info
Market Cap: $140.38M info
TARA
Apr 23, 2026, 8:41 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $5.26
Real-time Price: $2.28 info
Change: -$2.98 (-57%) info
Market Cap: $140.38M info
TARA
Apr 17, 2026, 4:15 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $5.34
Real-time Price: $2.28 info
Change: -$3.06 (-57%) info
Market Cap: $140.38M info
TARA
Mar 10, 2026, 8:11 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $5.72
Real-time Price: $2.28 info
Change: -$3.44 (-60%) info
Market Cap: $140.38M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets